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Background: Maternal obesity is associated with dysregulation of glucose and lipid 
metabolism with consequent exposure of the fetus to an abnormal metabolic milieu. It is 
recognized that maternal obesity predisposes offspring to chronic kidney disease (CKD). We 
aimed to determine whether the nuclear Farnesoid X receptor (FXR), known to play a role in 
maintaining homeostasis of glucose and lipid metabolism, is involved in renal injury in 
offspring of obese mothers.   
Methods: Maternal obesity was established in a rat model by feeding dams with high-fat diet 
prior to and during pregnancy and lactation. The offspring’s kidneys were examined at 
postnatal Day 1and Day 20. Human kidney 2 (HK2) cells were exposed to high glucose with 
or without the FXR agonist GW4064 or when FXR mRNA was silenced. 
Results: Glucose intolerance in the offspring of obese mothers was evident at weaning, with 
associated downregulation of renal FXR expression and upregulation of monocyte 
chemoattractant protein-1 (MCP-1) and transforming growth factor-β1 (TGF-β1). HK2 cells 
exposed to high glucose had reduced FXR expression and increased MCP-1, TGF-β1, 
fibronectin and collagen IV expression, which was reversed in the presence of GW4064. 
FXR-silenced HK2 cells had amplified pro-inflammatory and pro-fibrotic markers under high 
glucose conditions.  
Conclusions: Maternal obesity influences renal expression of pro-inflammatory and fibrotic 
factors that predispose the offspring to CKD. This was associated with the downregulation of 
the renal FXR expression suggesting a potential protective role for FXR.  
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Obesity is increasing in pandemic proportions worldwide, both in Western countries such as 
the United States and Australia but also in developing countries [1, 2]. Obesity clearly 
presents a personal risk for a range of future chronic disease, but when occurs during 
pregnancy and lactation has been shown to increase the risk of future chronic disease in the 
offspring [3-5]. Developmental programming is increasingly recognized as an important 
determinant of offspring health [3, 4, 6-10]. Indeed, offspring born to obese mothers are at 
increased risk of cardiovascular disease, stroke, diabetes and obesity itself [3, 5, 11]. There 
are many factors that influence disease risk, which include genetic predisposition, postnatal 
diet and lifestyle as well as maternal factors that affect the in utero environment. Animal 
models are a useful means by which to examine the effect of maternal obesity during 
pregnancy and lactation on offspring without the confounding factors of genetic background 
and adult lifestyle.  
 
Nuclear hormone receptors are ligand-activated transcription factors that regulate gene 
expression and are involved in many developmental, metabolic and endocrine functions [15]. 
The Farnesoid X receptor (FXR) is a nuclear hormone receptor critical in bile acid, glucose 
and lipid metabolism [15-21]. FXR is found in several tissues outside the enterohepatic 
system and in particular, is highly expressed in the kidney, with expression detected in 
glomeruli, mesangial cells, podocytes and proximal tubular cells (PTCs) [22]. FXR activation 
is associated with improved glucose metabolism and insulin sensitivity [19, 23]. Within the 
kidney, FXR activation downregulates lipogenic and fibrotic genes and reduces diabetes and 
obesity-related changes including glomerulosclerosis, tubulointerstitial fibrosis and 
proteinuria [24-29]. FXR null mice are at increased risk of developing diabetes and obesity-
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related nephropathy [25-27]. FXR is also important in the regulation of urine volume, and its 
activation increases the ability of renal tubules to concentrate urine [30]. 
 
Maternal obesity is likely to affect future kidney health in offspring. Several studies have 
shown that offspring born to diabetic mothers are at increased risk of hypertension, 
hyperfiltration and chronic kidney disease (CKD) [31]. Maternal obesity is yet more complex 
with dysregulated glucose, lipid and hormonal changes. Despite one report of a 22% 
increased risk of CKD in offspring of obese mothers, more conclusive evidence is lacking 
[32].  Obesity itself may lead to glomerulosclerosis and proteinuria [33]. Obesity related 
inflammation plays a significant role in the development and progression of renal damage in 
obesity [34-36]. There is also significantly more renal lipid accumulation within the kidneys 
of obese animals [26, 37].  
 
In this study, we aimed to investigate the effect of maternal obesity on the risk of CKD in the 
offspring in a rodent model and determine whether dysregulation of FXR expression is 
involved in this process. We hypothesized that FXR may be an important mediator of 
inflammatory and fibrotic pathways known to be involved in CKD and that maternal obesity 
may modulate these pathways. Therefore, we exposed HK2 cells to high ambient glucose to 
determine the effect on FXR expression, and investigate the effect of FXR activation and 
silencing on fibrotic and inflammatory mediators in those cells. 
 
Materials and Methods 
1. Animal model of maternal obesity 
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Twenty virgin outbred female Sprague Dawley rats (8-week old, Animal Resource Centre Pty 
Ltd, Perth, Australia) were maintained on 12h light/dark cycle, 20±2°C. They were randomly 
assigned to one of 2 groups with equal average body weight: (1) standard chow (11 kJ/g, 14% 
fat, Gordon’s Speciality Stockfeeds, NSW, Australia) or (2) high-fat diet (HFD, 20 kJ/g, 43% 
fat; Specialty Feeds, Perth, WA) [8]. After 5 weeks, females were mated, and, housed 
individually. The same diet was maintained during pregnancy and lactation until weaning. 
The study was approved by the Animal Care and Ethics Committee of the University of 
Technology Sydney (ACEC# 2009-350), and the “Australian code of practice for the care and use 
of animals for scientific purposes ” (NHM&RC, Australia) were followed. At birth, litter size 
was adjusted to 10 pups per mother (gender ratio: 1/1). An intraperitoneal glucose tolerance 
test (IPGTT) was performed at postnatal day 20. AUC was calculated for each rat. At 
postnatal Day 1 or Day 20, tissues from male offspring (n=8) were collected. Day 1 offspring 
were killed by direct decapitation. Day 20 offspring were anaesthetized (Pentothal® 0.1mg/g, 
i.p., Abbott Australasia, NSW, Australia) after overnight fasting. Blood were collected 
through cardiac puncture and blood glucose was measured immediately (Accu-Chek®, 
Roche Diagnostics, NJ, USA). Plasma was stored for lipids and hormonal determination. Left 
kidneys were snap frozen in liquid nitrogen and kept at -80°C for mRNA and protein 
quantification. Right kidneys were embedded in paraffin and sectioned for 
immunohistochemistry staining.  
 
2. Biochemical analyses 
Insulin concentrations were assessed using a radioimmunoassay kit (Linco, St Charles, USA). 
Plasma non-esterified fatty acid (NEFA) was measured using NEFA kit (WAKO, Osaka, 
Japan). In order to examine effects on renal function, Cystatin C was measured by 
immunoassay as per manufacturer’s instructions (R&D Systems, Minneapolis, USA).  
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3. In vitro cell culture of HK-2 cells 
HK-2 cells of a human proximal epithelial cell line from American Type Cell Collection 
(ATCC, USA) were used as previously described [38]. Cells were grown in 10 cm tissue 
culture dishes (Becton, Dickinson, NJ, USA), in keratinocyte serum-free media (KSFM) 
supplemented with bovine pituitary extract and epidermal growth factor (GIBCO). Initial 
‘dose-response’ experiments for FXR agonist GW4064 (Sigma Aldrich, USA) were 
undertaken to determine the concentration at which GW4064 maximally stimulated FXR 
protein expression, with minimal cytotoxicity. Exposure of HK2 cells to 1 M of GW 4064 
resulted in no cell toxicity. When the HK-2 cells were 60-70% confluent, they were exposed 
to the following experimental conditions for 24 hours prior to RNA extraction and 48 hours 
before protein extraction: 1) 5 mM D-glucose (ICN Biomedicals, Ohio, USA) (vehicle 
control); 2) 30 mM D-glucose; 3) 1 M GW 4064; 4) 1 M GW 4064 + 30 mM D-glucose 
and 5) 5 mM D-glucose + 25mM L-glucose as an osmotic control (ICN Biomedicals, Ohio, 
USA).  
 
4. Gene Silencing 
Gene silencing was performed using small interfering RNA (siRNA) strategies. Twenty-
seven-mer double-stranded RNA molecules were chemically synthesized (Shanghai 
GenePharma Co, Ltd, Shanghai, China). The complementary oligonucleotides were 2’-
deprotected, annealed, and purified by the manufacturer. The sequence specifically targeting 
human FXR (NR1H4) (accession no. NM_005123) was 5'-
GAUUGUUACUUCAACUCUATT-3', 5’ UAGAAUUGAAGUAACAAUCTT 3’. HK-2 
cells were plated in a 6-well plate. FXR siRNA (80 nmol/L) was introduced into HK-2 cells 
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using Lipofectamine 2000. In parallel, cells were transfected with a non-specific siRNA 
which served as a control. Twenty-four hours after transfection, both the control and the FXR 
silenced cells were exposed to 5 mM or 30 mM D-glucose for 48 hours. Silencing was 
confirmed by mRNA and protein expression.  
 
5. Relative quantitative real-time PCR (RT-PCR) 
RNA was extracted using RNeasy mini kit (Qiagen, Valencia, CA, USA). cDNA was 
generated using Transcriptor First Strand cDNA Synthesis Kits (Roche Diagnostics, 
Mannheim, Germany). RT-PCR was performed using an ABI Prism 7900 HT Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA) with SYBR GreenER qPCR 
Supermix (Invitrogen) and unlabeled PCR primers and SYBR probe (Applied Biosystems). 
Pre-optimized primer sequences are listed in Supplementary Data A. Results are presented as 
fold change compared to control after normalization to β-Actin.  
 
6. Immunohistochemistry (IHC)  
Formalin-fixed paraffin kidney sections were deparaffinised and incubated with the 
polyclonal primary antibody anti-FXR (1:50 dilution, Abcam Ltd, Cambridge) overnight, 
followed by horseradish peroxidase anti-rabbit Envision system (Dako Cytochemistry, Tokyo, 
Japan) the following day. Staining was developed with 3.3diaminobenzidine 
tetrahydrochloride (Dako Cytochemistry, Tokyo, Japan) before counterstaining with Mayer’s 
haematoxylin stains. Images were analysed using an Olympus microscope (Olympus, Japan) 
and Image J software.  
 
7. Immunofluorescence (IF) 
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Formalin-fixed paraffin kidney sections were deparaffinised and epitope was retrieved by 
boiling the tissues in sodium citrate (pH 6.0) for 20 min. Cells were permeabilised using 0.2% 
Triton-X100 (Sigma Aldrich). Tissues were then blocked in 10% blocking solution (Dako 
Cytochemistry) and incubated with SREBP1 primary antibody (1 in 100 dilution over night at 
4oC) (Abcam, Cambridge, USA). The immunohistochemical expression was visualized by 
means of anti-rabbit Alexa® Fluor 488 (FITC alternative, green fluorescent dye, Dako 
Cytochemistry) at 1:2000 dilution in serum for 1 h.  
 
8. Western blot analysis 
Protein was extracted from HK-2 PTCs lysate and western blotting were performed as 
previously described [39]. Briefly, 15 mg of total cell protein was mixed with 6X Laemmli 
sample buffer containing mercapto-ethanol and heated at 95°C for 10 min. Samples were 
then analyzed by SDS-PAGE in 2.5 to 10% Novex Bolt mini gels (Life Technologies, 
California, USA) and electroblotted to Hybond Nitrocellulose membranes (Amersham 
Pharmacia Biotech, Bucks, UK). Membranes were blocked in Tris-buffered saline containing 
0.2% Tween 20 (TTBS) in 5 % skim milk for 2 hours. Then primary antibodies against FXR 
1:1000 (Abcam); fibronectin 1:1000 (Sigma Aldrich), collagen IV 1:5000 (Abcam) and 
SREBP1c 1:1000 (Abcam)  were added and incubated overnight at 4 °C. Membranes were 
washed and incubated with horseradish peroxidase-conjugated secondary antibody for 2 
hours at room temperature, and washed. The membranes then were reprobed with β-Actin 
1:10000 (Santa Cruz, CA). Protein bands were visualized using the enhanced 
chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech). The bands 
corresponding to fibronectin (220kDa), collagen IV (250kDa), FXR (69kDa), SREBP1c 
(120kDa) and β-Actin (42kDa) were captured using LAS 4000 (Fujifilm, Tokyo, Japan), 
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corrected for -actin as a loading control. They were then analyzed using ImageJ software 
(v1.26r, National Institutes of Health, USA).  
 
8. Statistical analysis 
Results are expressed as mean ± SEM. The differences between the two groups were 
analysed by independent Student’s t-test. When there were more than 2 groups, one-way 
analysis of variance (ANOVA) was used, with post-hoc Fisher’s protected least-significant 
difference test (Prism 5, GraphPad Software, USA). P < 0.05 was considered significant.  
 
Results	
1. Effect of maternal obesity on the offspring of obese mothers  
Offspring of obese mothers had no difference in body weight at postnatal Day 1, compared to 
offspring of lean mothers (6.65 ± 0.42 vs. 6.68 ± 0.57g). Similarly, no differences in blood 
glucose or insulin levels were found (blood glucose: 5.15 ± 0.58 vs. 4.47 ± 0.49 mmol/L, 
plasma insulin 0.21 ± 0.05 vs. 0.18 ± 0.04ng/ml). However at postnatal Day 20, offspring of 
the obese mothers had significantly greater body weight compared to the offspring of lean 
mothers (p < 0.01; Table 1). In addition, offspring of obese mothers had increased adiposity; 
there was a 3-fold increase in retroperitoneal fat (p < 0.01) and a 4-fold increase in 
epididymal white adipose tissue (p < 0.01). The liver and kidneys were also heavier in 
offspring of the obese mothers (p < 0.05).  
After overnight fasting, blood glucose levels were higher in offspring of obese mothers (p < 
0.01, Table 1). Likewise, plasma triglycerides and NEFA were increased significantly in 
obese mothers’ offspring at Day 20 (p < 0.01).  
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At Day 20, offspring of obese mothers had significantly higher blood glucose concentrations 
at 15, 30, and 90 min during the IPGTT (p < 0.01, p < 0.05, p < 0.05, respectively, Fig. 1A). 
The AUC value was significantly higher in offspring of obese mothers (p < 0.05, Fig. 1B), 
suggesting impaired glucose metabolism in offspring of obese mothers. Insulin resistance, as 
measured by HOMA-IR was elevated in offspring of obese mothers (p < 0.001, Fig, 1C). 
Renal function, as measured by serum Cystatin C was not altered by maternal obesity (see 
Supplementary Data B). 
 
2. FXR and SREBP1c expression in the kidneys at postnatal Day 1 
and Day 20 
Renal expression of FXR mRNA was reduced in offspring of obese mothers compared to 
offspring of lean mothers at Day 1 (p < 0.05, Fig. 2A). This effect was sustained to Day 20 (p 
< 0.05, Fig. 2A).  Renal FXR protein change was consistent with mRNA changes at Day 20 
(p < 0.01, Figs. 2C and 2D). FXR activation is known to inhibit sterol regulatory element 
binding protein-1c (SREBP-1c) expression [40]. Although renal SREBP1c mRNA levels 
were not changed in offspring of the obese mothers at Day 1 or Day 20, the levels of 
SREBP1c protein expression were upregulated in the kidney from the offspring of the obese 
mothers at Day 20 as expected (p < 0.01, Figs. 2B, 2E and 2F).  
 
3. Offspring born to obese mothers had increased renal MCP-1 and 
TGF-β1 mRNA levels 
Renal monocyte chemoattractant protein-1 (MCP-1) was increased by four times in the 
offspring of the obese mothers compared to the control at Day 1 (p < 0.05; Fig. 3A). TGF-β1 
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was also increased in the offspring of obese mothers at Day 1 (p < 0.05; Fig. 3B). There was 
no statistically significance in MCP-1 and TGF-β1 expression at Day 20, 
 
4. Renal markers of extracellular matrix accumulation in offspring 
There was an increase in collagen IV at Day 1, but not Day 20 in offspring of obese versus 
lean mothers (p < 0.05; Fig. 3C). There was no change in fibronectin at either Day 1 or Day 
20 in offspring of obese mothers, suggesting little renal fibrotic change at this young age 
(Fig. 3D). 
 
5. High glucose down-regulates FXR expression and regulates its 
target genes in human HK2 cells 
Exposure to high glucose (30 mM D-glucose) significantly suppressed FXR mRNA 
expression by half and 2/3 at 24 and 72 hours respectively (p < 0.05, p < 0.01 respectively, 
Fig. 4A). This effect was not observed in cells cultured in 25 mM L-glucose + 5 mM D-
glucose, which served as an osmotic control. Given the known reciprocal relationship 
between FXR and small heterodimer protein (SHP) and SREBP-1c activation, SHP and 
SREBP-1c were examined. No difference in SHP mRNA expression in low or high glucose at 
24 hours was seen (Fig. 4B). However, 72-hour exposure to high glucose was associated with 
down-regulation of SHP compared to cells exposed to 5 mM D-glucose (p <0.01; Fig. 4B). At 
72 hours, SREBP-1c mRNA was markedly upregulated in the HK-2 cells exposed to high 
glucose compared to those exposed to 5 mM D-glucose (p < 0.001; Fig. 4C).  
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6. FXR agonist inhibits high glucose-induced fibronectin and 
collagen IV expression  
The extracellular matrix proteins fibronectin and collagen IV are commonly overexpressed in 
the early stages of CKD. To determine the effect of high glucose on the expression of 
fibronectin and collagen mRNA, HK-2 cells were exposed to high glucose for 24 hours. This 
resulted in an increase in fibronectin and collagen IV compared to the vehicle control (p < 
0.05, Figs. 5A and B respectively). Co-incubation with GW4064 reversed the effect of high 
glucose on mRNA expression of fibronectin and collagen IV (p < 0.01, Figs. 5A and B). 
Similarly, protein expression of both fibronectin and collagen IV was reduced (p < 0.05, Figs. 
5C and D). 
To confirm this finding, protein expression of fibronectin and collagen IV was examined in 
HK-2 cells after 48 hours incubation with high glucose in the presence or absence of 
GW4064. Fibronectin protein expression was nearly doubled compared to the control cells 
when exposed to high glucose (p < 0.01, Fig. 5C). Similarly, type IV collagen production was 
also significantly increased in the HK-2 cells by high glucose exposure (p < 0.05, Fig. 5D). 
GW4064 suppressed high glucose-induced fibronectin and type IV collagen production in the 
HK-2 cells (p < 0.01, Fig. 5C and p < 0.05, Fig. 5D respectively).  
 
7. FXR agonist inhibits high glucose-induced TGF-β1 and MCP-1 
expression 
TGF-β1 mRNA expression was significantly increased following 24 hours exposure to high 
glucose compared to the control group (p <0.05; Fig. 6A), which was inhibited by GW4064 
(p < 0.01). MCP-1 mRNA expression was also significantly increased by high glucose, but 
not ameliorated by additional GW4064 co-incubation (Fig. 6B). 
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8. FXR silenced cells had increased fibronectin, type IV collagen 
and SREBP-1 expression 
FXR silencing was confirmed by both mRNA and protein expression of FXR. A 50-60% 
reduction of FXR protein expression was achieved in all experiments compared to the control 
(data not shown). 
There was increased extracellular matrix markers in FXR silenced HK-2 cells compared to 
cells transfected with non-specific siRNA. Both fibronectin and type IV collagen expression 
were increased in FXR silenced cells (p < 0.01, p < 0.05, Figs. 7A and B, respectively). 
Exposure to high glucose conditions (30 mM D-glucose for 72 hours) increased fibronectin 
expression in both normal and FXR-silenced cells but significantly more so in the FXR-
silenced cells (p < 0.05, FXR-silenced vs. normal). Similarly, type IV collagen expression 
was increased in HK-2 when FXR was silenced (p < 0.05) or exposed to high glucose (p < 
0.05), which was further increased to in FXR silenced cells exposed to high glucose (p<0.05, 
Fig. 7B).  
Increased SREBP-1 expression was found in FXR silenced cells compared to cells treated 
with non-specific siRNA (p < 0.05, Fig. 7C). Exposure to 30 mM D-glucose further increased 
SREBP-1 expression in cells with silenced FXR, confirming that FXR can inhibit the 
expression of SREBP-1 (Fig. 7C).  
 
Discussion 
This study demonstrates that maternal obesity has significant adverse effects on the 
offspring’s kidneys and may increase the risk of kidney damage later in life. This study 
 15
suggests that suppressed renal FXR is critical for maternal obesity-induced nephropathy in 
offspring, which has not been reported previously. 
Growing evidence has suggested that dysregulation in glucose as well as lipid metabolism 
may play a major role in the pathogenesis of obesity-related nephropathy [26, 28, 29, 37, 41-
44]. Despite the known relationship between obesity-related nephropathy and glucose 
dysregulation and dyslipidemia, the contribution of FXR regulation to renal damage has not 
been well characterized. Our in vivo study showed that offspring of obese mothers have 
reduced renal expression of FXR until at least weaning in rats. FXR is mainly expressed in 
the tubules, but not in the glomeruli, as shown in this study and reported previously by others 
[45]. In vitro study using human proximal tubule epithelial cell line demonstrated that high 
ambient glucose inhibits FXR expression and that the activation of FXR mitigates the effects 
of high ambient glucose to increase pro-inflammatory, pro-fibrotic mediators and 
extracellular matrix accumulation of collagen IV and fibronectin, which are the first step 
towards the development of CKD. Furthermore, FXR silencing markedly enhanced the effect 
of high glucose on inflammatory, fibrotic and lipid pathways in PTCs. These results suggest a 
significant role of FXR in modulating inflammation and fibrosis within PTCs under high 
glucose conditions. This is not surprising given FXR has already been shown to play a role in 
the development of hepatic fibrosis [23, 24, 46].  
Bile acids can cross the blood-placenta barrier. In addition, fetal and maternal bile acid levels 
are well correlated. Bile acid accumulation in the bloodstream induces intrahepatic 
cholestasis of pregnancy (ICP). A recent study by Papacleovoulou et al. showed that children 
born to pregnant women with ICP had higher body mass indices and increased fasting 
hyperinsulinaemia at age 16 despite normal birth weight [47]. The offspring of mothers with 
ICP were more prone to obesity and diabetes [47]. In our study, offspring were exposed to 
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overnutrition due to maternal obesity including increased fatty acids, cholesterol, glucose and 
other nutrients, all of which may impact upon FXR expression in the kidney.  
The role of inflammation in the development of CKD is increasingly appreciated. We 
recently reported that inflammatory mediators are important for the development of fibrosis 
within PTCs [48]. We showed that in the presence of high glucose, transforming growth 
factor-1 (TGF-1) expression is induced and in particular, TGF-1 plays a major role in 
upregulating other proinflammatory cytokines, including MCP-1 [49]. These cytokines 
directly regulate the activity of pro-fibrotic markers, including fibronectin and collagen IV 
[49]. FXR has been shown to negatively interfere with the inflammatory response [50]. Wang 
et al. showed that obese mice had increased expression of MCP-1 and reduced expression of 
anti-inflammatory cytokine Kruppel-like factor 4 within their kidneys [26]. In this study, 
offspring of obese mothers had increased MCP-1 and TGF-1 despite no difference in their 
body weight at postnatal Day 1 suggesting an intrauterine programming. Our in vitro model 
demonstrated that activation of FXR using agonist can reduce expression of MCP-1 and 
TGF-1 as well as fibrotic markers fibronectin and collagen IV; while silencing FXR had the 
opposite effect. Similarly, the FXR ligand (6-ethyl chenodeoxycholic acid) has been shown to 
have anti-fibrotic, anti-inflammatory and anti-apoptotic effects in cisplatin-induced HK-2 
cells [51]. Interestingly, here in rats, despite in utero exposure to high-fat diet there appeared 
to be minimal effects on pro-fibrotic markers. It is likely that fibrotic changes would be 
evident at later time points as it was demonstrated in the study performed by Hao et al. 
showing significant extracellular matrix (ECM) changes after 3 months post-birth [52]. 
Previous studies have suggested that FXR activation has beneficial effects on the kidney by 
altering the expression of SREBP-1 and its lipogenic target genes [53]. SREBP-1 is a known 
key transcriptional factor linking fatty acid and lipid accumulation to ECM deposition [18, 
43]. In SREBP-1 transgenic mice, overexpression of SREBP-1 in the kidney caused lipid 
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accumulation and increased expression of profibrotic cytokines, which induced ECM 
accumulation, mesangial expansion, glomerulosclerosis and proteinuria [44]. SREBP-1c lies 
downstream of FXR [40]. SREBP-1c is known to be expressed in human and animal tissues, 
in particular kidneys [54, 55]. Although mRNA expression of FXR in mouse PTCs is five 
times more than in glomeruli, there is a lack of evidence linking FXR with SREBP-1c in 
kidney PTCs [25].  In our HK2 PTCs, high glucose was associated with downregulation of 
FXR and SHP with upregulation of SREBP-1c. Similarly, the downregulation of FXR was 
associated with an upregulation of SREBP1c protein expression in offspring from obese rats 
at weaning. 
Suckling from obese mothers may confound the maternal effects incurred in utero. Previous 
studies addressed this confounding problem by cross-fostering techniques [4], thereafter to 
conclude that in utero exposure has independent effects on organ development and 
metabolism. Interestingly changes in FXR were demonstrated at Day 1 before significant 
neonatal milk consumption. In addition, changes in MCP-1, TGF-β1 and collagen IV were 
also evident at Day 1. These changes had mostly normalized by postnatal Day 20, suggesting 
postnatal milk intake may have ameliorated the intrauterine effect due to maternal HFD 
consumption. It is well documented that breastfeeding has significant protective effects 
against obesity and its related metabolic effects [56-58] possibly due to increased amounts of 
antioxidants in the breast milk [59]. Nevertheless, we postulate that the future development of 
CKD may require a second insult such as HFD consumption. The effect of maternal obesity 
when a second insult is incurred may affect renal inflammatory and fibrotic markers in 
addition to renal pathology and function in adult offspring which will be the focus of future 
research. 
Offspring of obese mothers had glucose intolerance at weaning; therefore we pursued the role 
of FXR in glucose-mediated renal damage in our in vitro model. Indeed, we showed that 
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FXR is linked to glucose-mediated inflammatory and fibrotic changes in PTCs. Taken 
together, basal FXR expression is important in maintaining ECM homeostasis and high 
glucose suppresses FXR expression. In addition, an FXR agonist can abrogate high glucose-
induced ECM production. However, the offspring of obese mothers also had impaired lipid 
metabolism at Day 20. We did not investigate the role of FXR in lipid/cholesterol-mediated 
damage to PTCs here. Other nuclear hormone receptors such as vitamin D receptor (VDR) 
and peroxisome-proliferator-associated receptors (PPARs) are known to play a role in renal 
inflammation, oxidative stress, fibrosis and renal lipid deposition and their activation may 
mitigate nephropathy in diabetic animals [60]. Nuclear receptor activation of FXR, VDR and 
PPAR tend to have common pathways leading to modulation of glucose metabolism, lipid 
metabolism and immune response [60-62]. 
FXR is a potential pharmacological target for the treatment of obesity and metabolic 
syndrome due to its regulation of bile acids, lipids and glucose metabolism [18, 20, 21, 23, 
26]. Weight reduction induced by sleeve gastrectomy was recently demonstrated to be 
critically dependent upon FXR activation [63]. Indeed, FXR knockout mice with dietary 
obesity failed to lose significant weight with sleeve gastrectomy compared to their wild-type 
counterparts. The therapeutic benefit of FXR agonists is only just being explored. A clinical 
trial investigating the effect of the FXR agonist INT-747 in patients with type 2 diabetes and 
non-alcoholic fatty liver disease, concluded that FXR activation improved insulin sensitivity 
and reduced markers of liver inflammation and fibrosis [64].  More clinical trials are 
underway to determine the effect of FXR agonist in the setting of diabetes and non-alcoholic 
fatty liver disease [65].  
 
Several studies have shown that FXR activation can ameliorate diabetic nephropathy by 
modulating lipid metabolism, fibrosis, inflammation, and oxidative stress in animals and in 
 19
glomerular and mesangial cells in vitro [25, 66, 67]. This study suggests that this process also 
occurs in PTCs. Furthermore, maternal obesity can change renal FXR expression associated 
with dysregulated glucose and lipid levels in the offspring. Our study is the first to report the 
effect of maternal obesity, which is a global health issue in humans, on the offspring’s kidney, 
and linked it to FXR as a critical regulator of the developmental programming effect of 
maternal obesity on kidney health. The long term effects of a reduction of FXR level in early 
post-natal life on the development of CKD requires further investigation. If proven, the 
relative benefits of modifying FXR in the offspring of obese mothers will necessitate future 
study 
 
In summary, maternal obesity downregulates renal FXR expression in the offspring kidney, 
which is associated with increased inflammation and early fibrotic change in the kidney at 
birth. Given the role that FXR plays in regulating lipid and glucose metabolism, with 
downstream activation of inflammatory and fibrotic pathways, the potential exists for FXR 
modulation to prevent and ameliorate kidney damage associated with maternal obesity.   
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Body weight (g) 59.3 ± 0.5 71.5 ± 2.8  ** 
Retroperitoneal fat (mg) 71.5 ± 3.8 287.9 ± 24.6 ** 
Epididymal fat (mg) 95.5 ± 4.9 483.4 ± 45.5 ** 
Liver (g) 2.80 ± 0.04 3.48 ± 0.17 * 
Kidney (mg) 347.3 ± 5.9 375.3 ± 11.4 * 
Fasting blood glucose (mM) 5.54 ± 0.16 6.11 ± 0.09 ** 
Plasma insulin (ng/ml) 0.37 ± 0.07 0.60 ± 0.07 * 
Plasma triglycerides (mM) 0.21 ± 0.03 1.29 ± 0.24 ** 
Plasma fatty acids (mM) 0.94 ± 0.05 1.41 ± 0.14 ** 




Fig. 1.  Offspring of obese mothers have reduced glucose tolerance at weaning. 
IPGTT at postnatal Day 20 (A). AUC depicted in (B). (C) Insulin resistance measured by 
HOMA-IR. N = 8 per group. * p < 0.05, ** p < 0.01, *** p < 0.001 
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Fig. 2. FXR was downregulated in the kidneys of offspring of obese mothers at postnatal 
Days 1 and 20. 
mRNA expression of FXR (A) and its downstream target SREBP-1c (B) at postnatal Days 1 
and 20 (B). IHC staining (C and E) and quantification (D and F) of FXR and SREBP1c at 
Day 20. Images shown at 400x magnification. N = 5-7 per group, * p < 0.05 and ** P<0.01. 
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Fig. 3. mRNA expression of TGF-β and MCP-1 was upregulated in the kidneys of offspring 
of obese mothers at Day 1 but not at Day 20. Collagen IV but not fibronectin was increased 
in offspring of obese mothers at Day 1 but not at Day 20.  
Renal mRNA expression of MCP-1 (A), TGF-β1 (B), Collagen IV (C) and fibronectin (D) at 
postnatal Day 1 and Day 20. N = 5-7 per group, * p < 0.05, ** p < 0.01. 
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Fig. 4. Effect of high glucose on FXR expression in HK-2 cells 
HK-2 cells were exposed to 5 mM D-glucose (white open bar) or 30 mM D-glucose (black 
solid bar) for 24 or 72 hours. mRNA expression of FXR (A), SHP (B), and  SREBP-1c (C) at 
24 and 72 hours. N = 3 per group, *p<0.05, ** p < 0.01, ***p<0.001. 
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Fig. 5. Suppression of high glucose-induced fibronectin and collagen-IV expression by 
GW4064 in HK-2 cells 
mRNA and protein expression of fibronectin (A and C) and Type IV collagen (B and D) 
exposed to high-glucose with and without the presence of GW4064 in HK-2 cells. N = 4 per 
group, * p<0.05; ** p < 0.01. 
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Fig. 6. Exposure of HK-2 cells to high glucose increases TGF- β and MCP-1 mRNA 
expression and GW4064 ameliorates this effect. 
mRNA expression of TGF-β (A) and MCP-1 (B)  in HK-2 cells exposed to high glucose with 
and without the presence of GW4064. N = 4-5 per group, * p < 0.05, ** p < 0.01. 
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Fig. 7. FXR silenced cells exhibit increased ECM and SREBP-1 expression, further 
upregulated by exposure to high glucose conditions. 
Protein levels of fibronectin (A), type IV collagen (B), and SREBP-1c (C) in FXR silenced 
cells exposed to 5 mM D-glucose (black solid bar) and 30 mM D-glucose (white empty bar) 
for 72 hours. N = 4-5 per group, * p < 0.05, ** p < 0.01. 
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